Nigeria US Health Compact and The Duty To Inform
Public Transparency Critical in Nigeria’s Health Agreement with U.S.
Public confidence in international agreements hinges critically not only on the negotiations themselves but also on the government’s commitment to disclose, explain, and defend the terms of these agreements.
Nigeria’s recent health agreement with the United States has sparked discussions about transparency and governance. While the government may have crafted a defensible framework, many citizens are left to piece together its implications from interviews given by foreign officials and disjointed information available online.
This situation highlights a significant governance challenge: the inadequate public explanation of a crucial national decision. “Public scrutiny requires access to the terms of agreements made in citizens’ names,” advocates stress.
Former Ghanaian President John Dramani Mahama’s remarks about his country’s rejection of a similar health compact have intensified the scrutiny surrounding Nigeria’s arrangement. Speaking at the Council on Foreign Relations on September 25, 2026, Mahama raised concerns about issues such as pathogen information, medical records, domestic financing, and the inspection of incoming medical products. However, his comments do not clarify the precise terms accepted by Nigeria.
This distinction is crucial. There is insufficient evidence to confirm that Nigeria has adopted the same conditions that Ghana rejected. A common American policy framework does not guarantee identical agreements, and responsible public debate must not confuse similarities with proof.
Critics argue that the Nigerian government’s public communications have not sufficiently established a basis for a robust defense of the agreement. At the same time, an information deficit does not validate every concern that has been raised.
The Federal Ministry of Health announced the agreement in December 2025, detailing its objectives and the anticipated influx of nearly $2 billion in U.S. grants against almost $3 billion in Nigerian financing. The partnership was positioned as a step toward self-reliance, but this description leaves many questions about specific conditions unanswered.
The memorandum of understanding (MoU) released by Nigeria includes certain safeguards, such as requiring case-by-case approvals for specimen sharing, regulated audit access, and a commitment to respect relevant laws regarding data ownership and hosting. Notably, it asserts a non-binding nature, and there appears to be no blanket restriction on inspections of American medical products by the National Agency for Food and Drug Administration and Control (NAFDAC).
However, analysts call for deeper scrutiny of the separate specimen-sharing agreement, which allows sharing with qualifying U.S. entities with prior notice to Nigeria. Access to resulting medical countermeasures is contingent on funding availability and legal considerations, and termination of the agreement does not halt U.S. use of previously shared materials.
This agreement took effect in January 2026 and is set for a five-year term, which may be renewed by mutual consent. Citizens should have been made aware of these substantive provisions alongside the announcement of associated benefits.
Documentation from Public Citizen includes the Nigerian MoU and specimen agreement but lacks a clear text on data-sharing criteria. Absent this document, a full assessment of the data-access obligations remains elusive.
Effective governance requires sound information management. This begins with accurate record-keeping, accountability for decisions, accessible disclosures, and the ability for citizens to differentiate between obligations and aspirations. It also involves rectifying public misunderstandings.
Questions regarding public health data and biological resources are valid and need addressing. Citizens deserve to know who has access to their information, the lawful purposes for which it may be used, and the conditions of transfer. Clarifications are needed on Nigeria’s gains from products developed using its specimens, who holds the authority to refuse data transfers, and the impact on essential services if funding is withdrawn.
A government undermines its negotiation leverage if it fails to provide comprehensive explanations of such arrangements. If Nigeria has secured more robust protections than are available elsewhere, the public must see that reflected in official documents. Conversely, if there are weaknesses, transparency enables institutions to address these before they escalate into larger issues.
To improve management of this agreement, Nigeria should first publish a complete, verified set of documents on an official platform, including the signed MoU, related agreements, and any pending negotiations, along with a clear chronology of updates. Each document should come with a date and version history, and explanations should thoroughly differentiate U.S. funding from Nigerian expenditures.
While protecting sensitive patient information is essential, it should not impede the publication of the regulations governing its use. Additionally, the government should evaluate the agreement’s overall impact, detailing considered alternatives, expected benefits, and potential risks.
Regulatory bodies must also provide clarity: NAFDAC should assert its ongoing authority regarding inspections and enforcement; the Nigeria Data Protection Commission should illuminate privacy issues and oversight for cross-border health data access; while the Nigeria Centre for Disease Control and Prevention should clarify the public health rationale and protocols for specimen transfers.
Legislative oversight should encompass the entire agreement, not just its financial aspects, prompting relevant committees to hold public hearings that include stakeholders from various sectors.
Finally, Nigeria needs to create measurable safeguards for agreement implementation, enabling public reporting on transfer volumes and recipient categories while protecting individual patient details. Independent audits should consistently verify compliance, and the government should seek stronger controls on secondary use of shared data to ensure affordable access to resulting health products.
In conclusion, Nigeria’s health agreement with the United States must remain open to public debate, especially in light of Mahama’s remarks. The government is tasked with validating its decisions through thorough, accessible evidence, reinforcing health sovereignty and enabling transparency regarding commitments made on behalf of its citizens. It cannot afford to shroud itself in secrecy, as effective governance necessitates the ability to withstand public inquiry—something that only comprehensive, clear information can support.
—By Collins Nweke
